Introduction {#Sec1}
============

Major depressive disorder (MDD) is one of the most common psychiatric disorders, which involves dysregulation of affect, motivation, appetite, sleep, and cognitive dysfunctions, resulting in impairments in several aspects of life. An accumulating body of research indicates that MDD is often the result of the interplay between genetic vulnerability and environmental factors (Kendler [@CR25]). In particular, child abuse (CA) is a significant etiological factor in the development and persistence of MDD across the life cycle (Charney [@CR9]; Heim and Nemeroff [@CR19]; McLaughlin et al. [@CR28]; Spinhoven et al. [@CR41]). Moreover, exposure to stress during adulthood (for example, divorce and job loss) often precipitates or exacerbates depressive symptoms (Kendler et al. [@CR26]). In some instances, stressful events in adulthood interact with stressful events that occurred early in life to contribute to the process of stress sensitization (Post [@CR35]).

Given its major contribution to the burden of disease, it is important to identify underlying biological mechanisms that might lead from stress exposure to MDD. One of the neurobiological changes that may be triggered by both chronic and acute stress is a downregulation of brain-derived neurotrophic factor (BDNF). The neurotrophin BDNF is a critical regulator of the formation, plasticity, and integrity of neurons in brain circuits that regulate emotion (Angelucci et al. [@CR3]; Duman and Monteggia [@CR13]). In animals, exposure to stress early in life (for example, repeated maternal separation) has been found to induce a relative decrease in the expression of BDNF and to subsequent neuronal atrophy and degeneration in the hippocampus and the cortex, which can persist into adulthood (Murakami et al. [@CR30]; Roceri et al. [@CR36]; Song et al. [@CR40]; Smith et al. [@CR39]). According to the "neurotrophic hypothesis of depression," these reductions in BDNF expression may account for the pathophysiology of MDD (Duman and Monteggia [@CR13]). Consistent with this idea, several studies found decreased central (Karege et al. [@CR22]) and peripheral levels of BDNF (Molendijk et al. [@CR29]; Sen et al. [@CR38]) in patients with MDD. More specifically, in line with the animal models, one study found lowered plasma BDNF in depressed women with a history of childhood physical neglect compared to nonabused depressed women and controls (Grassi-Oliveira et al. [@CR17]). A study among bipolar patients reported similar reductions in serum BDNF levels in patients exposed to stressful life events (Kauer-Sant'Anna et al. [@CR23]).

A common single-nucleotide polymorphism (SNP) on the BDNF gene is Val^66^Met. Val^66^Met refers to a valine (Val) to methionine (Met) insertion at codon 66 (Egan et al. [@CR15]). This SNP affects intracellular processing and secretion of BDNF, with the Met allele being associated with a decrease in activity-dependent secretion of BDNF compared to the Val allele (Egan et al. [@CR15]). Most studies have compared carriers of a Met allele (Val/Met) with individuals who are homozygous for the Val allele (Val/Val) because individuals who are homozygous for the Met allele (Met/Met) are rare in Caucasians (approximately 4%). In general, these studies have shown that Met carriers have lower hippocampal gray matter (Bueller et al. [@CR8]; Pezawas et al. [@CR34]) and poorer episodic memory performance (Egan et al. [@CR15]) compared to individuals homozygous for the Val allele. Moreover, several studies have reported that Met carriers are more vulnerable to the effects of CA compared to individuals who are homozygous for the Val allele in terms of depressive symptoms (Kaufman et al. [@CR24]; Wichers et al. [@CR46]) and hippocampal gray matter (Gatt et al. [@CR16]).

Whereas variations on the BDNF gene seem to play an important role in MDD, little is known on how variations on the BDNF polymorphism Val^66^Met may influence serum BDNF levels of individuals who have been exposed to CA and/or recent negative life events. A closer examination of the impact of CA and recent life stress and the moderating role of variations on the BDNF polymorphism Val^66^Met on blood-derived BDNF levels may help to elucidate the neurobiological changes that underlie the susceptibility of developing MDD after exposure to stressful life events. Therefore, using data from the Netherlands Study of Depression and Anxiety (NESDA, see Penninx et al. [@CR33]), we investigated, cross-sectionally, the impact of CA and recent life events on serum BDNF levels in a large sample of individuals with lifetime MDD (*n* = 1,435) and assessed whether the impact of these stressful life events was moderated by variations on the BDNF Val^66^Met polymorphism (comparing Met carriers to homozygous Val carriers). Based on findings in animals and humans, we hypothesized that both CA and recent life events would reduce serum BDNF levels, particularly in Met carriers of the Val^66^Met polymorphism.

Materials and methods {#Sec2}
=====================

Participants {#Sec3}
------------

Participants were derived from NESDA (for details on the design, objectives, and protocol of NESDA, see Penninx et al. [@CR33]). In brief, NESDA is a prospective cohort study (*N* = 2,981) that recruited subjects with a current MDD and/or an anxiety disorder, patients with MDD and/or an anxiety disorder in remission, and healthy controls without a history or current MDD or anxiety disorder in specialized mental health care, primary care, and the general population. A general inclusion criterion was an age of 18 through 65 years. Excluded were individuals with a primary diagnosis of psychotic, obsessive compulsive, bipolar, or severe addiction disorder (requiring care in specialized addiction clinics). A second exclusion criterion was not being fluent in Dutch. At baseline, participants provided blood and underwent a medical examination. The study protocol was approved by the Ethical Review Board of the VU University Medical Center and by local review boards of each participating institute. After full information about the study was provided, written informed consent was obtained from all participants.

From the NESDA baseline sample, we selected 1,435 participants (48.1%), with a mean age of 42.2 years (±12.4) and 30.7% (*n* = 440) males. To investigate individuals with a vulnerability to MDD, our selection was based on the following criteria: (1) participants had to have a current or lifetime diagnosis of MDD; (2) genomic data, data on serum BDNF levels, and measurements of CA and recent stress had to be available; and (3) participants had to be of North-European descent.

DSM-IV diagnoses (APA [@CR2]) of MDD and anxiety disorders (generalized anxiety, social phobia, panic with or without agoraphobia, or agoraphobia without history of panic) were determined by means of the Composite Interview Diagnostic Instrument (CIDI; Wittchen et al. [@CR47]) that was administered by trained research staff. The CIDI has high reliability (Wacker et al. [@CR45]) and validity (Wittchen et al. [@CR47]). Depression symptom severity was assessed using the Inventory of Depressive Symptoms Self-Report version (Rush et al. [@CR37]). The use of antidepressants was gauged on by self-report and drug container observation.

CA was assessed retrospectively using a semistructured childhood trauma interview, previously used in the Netherlands Mental Health Survey and Incidence Study (de Graaf et al. [@CR11], [@CR12]). In this interview, participants were asked whether they had experienced before the age of 16 years one of the following types of trauma: emotional neglect, psychological, and physical and/or sexual abuse. Emotional neglect was described as "Nobody ever listened to you at home, your problems were ignored, you had the feeling not being able to find any attention or support from your parents." Psychological abuse was described as "You were verbally abused, unjustly punished, your brothers and sisters were favored, but no bodily harm was done." Physical abuse was defined as "Being kicked, hit with or without an object, or being physically maltreated in any other way." Sexual abuse was defined as "Being touched sexually by anyone against your will, or being forced to touch anyone sexually." After an affirmative answer, details on the frequency of these events and the perpetrators involved were asked for. Because of the large overlap between emotional neglect and emotional abuse, the two types of abuse were merged together as "emotional abuse." Answers were coded as zero, one, two, or three reported types of CA. The mean number (±standard deviation (SD)) of CA types was 1.12 (±1.15), with 42.7% (*n* = 613) reporting no CA, 21.6% (*n* = 310) reporting one type of CA, 17.1% (*n* = 246) reporting two types of CA, and 18.5% (*n* = 266) reporting three types of CA. For the main analysis of variance (ANOVA), the presence of CA was defined as 0 versus ≥1 type of CA. For dose--response analyses, individuals were divided into three categories: individuals reporting no CA, one type of CA, and two or more types of CA.

The occurrence of 12 recent stressful life events ("recent stress") was assessed using the List of Threatening Events Questionnaire (LTE-Q; Brugha et al. [@CR7]; Brugha and Cragg [@CR6]). These events reflect the presence of life stressors during the past year, such as serious illness and injury, death of close friend or relative, unemployment, major financial loss, and loss of important relationships. The LTE-Q has good test--retest reliability, high agreement between participant and informant ratings, and good agreement with interview-based ratings (Brugha and Cragg [@CR6]). Answers were coded as the total number of life events. The mean number (±SD) of reported stressful life events was 0.68 (±1.0), with 58.4% (*n* = 838) reporting no life events, 23.6% (*n* = 338) reporting one event, 12.1% (*n* = 173) reporting two events, 4.5% (*n* = 64) reporting three events, 0.6% (*n* = 9) reporting four events, 0.6% (*n* = 9) reporting five events, 0.2% (*n* = 3) reporting six events, and 0.1% (*n* = 1) reporting seven events. For the main analyses, "recent stress" was defined as 0 versus ≥1 incidents of stressful life events during the preceding year, whereas for the dose--response analyses, individuals were divided into three groups: individuals reporting no life event, one life event, and two or more life events in the past year.

Genotyping {#Sec4}
----------

Genotyping of the subjects was performed by Perlegen Sciences using high oligonucleotide arrays (Mountain View, CA, USA). For detailed descriptions on the procedures according to which genotyping was performed, we refer to Boomsma et al. ([@CR5]). The Val^66^Met polymorphism (Dibisnp 6265) was extracted from whole genome data using PLINK software (<http://pngu.mgh.harvard.edu/~purcell/plink>). Val^66^Met was in the equilibrium as stated by Hardy and Weinberg (*P* = .28). Moreover, genotype frequencies (Val^66^Val 65.5%, Val^66^Met 32.5%, and Met^66^Met 2%) were similar to those reported in previous studies on Caucasian populations (Gatt et al. [@CR16]; Lang et al. [@CR27]). Individuals who were homozygous for the Met allele were merged with the heterozygous individuals into a group of Met carriers (*n* = 495) and compared to homozygous Val carriers (*n* = 940).

Serum BDNF measurements {#Sec5}
-----------------------

Fifty milliliters of blood was withdrawn into vacuum tubes between 07:30 a.m. and 09:30 a.m. after an overnight fast. Following blood collection, serum was separated and stored at −85°C until it was assayed. BDNF protein levels were measured using the Emax ImmunoAssay system from Promega according to the manufacturer's protocol (Madison, WI, USA). Greiner Bio-One high-affinity 96-well plates were used. Serum samples were diluted 100 times, and the absorbency was read in duplicate using a Bio-Rad Benchmark microplate reader at 450 nm. Serum BDNF protein levels were expressed in nanograms per milliliter. The intra-assay and inter-assay coefficients of variation were within 3% and 9%, respectively. Prior to analyses, BDNF values that were three SD above the mean (*n* = 5, 0.35%) were trimmed to a value of the mean plus three SDs. One BDNF value (0.07%) was below the reliable detection limit of the ELISA kit of 1.56 ng/ml and was set at the lower detection limit of 1.56 ng/ml.

Statistical analysis {#Sec6}
--------------------

ANOVAs and *χ*^2^ tests were used to determine between-group differences in demographical and clinical features (see Table [1](#Tab1){ref-type="table"}). Table 1Demographic and clinical characteristics by brain-derived neurotrophic factor genotype (Val^66^Met) and exposure to child abuse and recent stressful events (*N* = 1,435)Val^66^Val (*n* = 940)Val^66^Met (*n* = 495)*P* valueNo abuse (*n* = 388)Abuse (*n* = 552)No abuse (*n* = 225)Abuse (*n* = 270)No recent stress (*n* = 237)Recent stress (*n* = 151)No recent stress (*n* = 309)Recent stress (*n* = 243)No recent stress (*n* = 138)Recent stress (*n* = 87)No recent stress (*n* = 154)Recent stress (*n* = 116)Male, %38.032.525.926.331.237.931.827.6\<.05^a^Age (years)42.3 ± 12.838.5 ± 13.744.1 ± 11.442.2 ± 11.841.8 ± 13.339.5 ± 12.744.4 ± 11.741.7 ± 12.5\<.01^a,\ b^Education (years)12.3 ± 3.112.1 ± 3.212.2 ± 3.411.8 ± 3.312.1 ± 3.011.2 ± 3.112.0 ± 3.111.4 ± 3.3.06Body mass index26.2 ± 4.925.1 ± 4.425.7 ± 5.326.0 ± 5.325.3 ± 4.925.4 ± 4.826.5 ± 5.425.7 ± 5.6.23Smoker, %31.342.938.041.834.148.83.348.2\<.01^b^Alcohol dependent, %13.913.622.023.918.814.920.829.3\<.01^a^Emotional abuse, %NANA93.894.8NANA94.496.3.79Physical abuse, %NANA27.834.9NANA27.140.4\<.05^b^Sexual abuse, %NANA38.229.3NANA29.238.5.09\>1 event of abuse, %NANA63.164.2NANA53.967.2.10\>1 event of recent stress, %NA47.7NA43.2NA58.6NA32.8\<.05^a^Current MDD (6 months), %46.454.357.968.359.454.054.569.8\<.001^a,\ b^Chronic MDD^c^24.322.728.133.221.528.224.637.4\<.05^a,\ b^MDD severity (IDS)22.1 ± 12.824.3 ± 12.427.7 ± 13.231.2 ± 12.424.0 ± 13.523.2 ± 13.526.7 ± 13.129.7 ± 11.6\<.001^a,\ b^Comorbid anxiety^d^, %30.028.541.449.833.333.235.146.6\<.01^a,\ b^Antidepressant use^e^, %35.033.139.342.830.426.439.644.0\<.05^a^*IDS* inventory of depressive symptoms, *MDD* major depressive disorder^a^There is a difference at *P* \< .05 between the no abuse group and the abuse group^c^There is a difference at *P* \< .05 between the no recent stress group and the recent stress group^c^Symptoms were considered chronic if they were present for at least 24 months during the last 5 years^d^Included a diagnosis of social phobia, panic disorder with and without agoraphobia, agoraphobia, or generalized anxiety disorder during the last six month^e^Included the use of noradrenergic and specific serotonergic antidepressants, serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, St. John's wort, and tricyclic antidepressants

Estimates of the main and interaction effects of CA, recent stress, and Val^66^Met on serum levels of BDNF were performed using 2 (CA: yes/no) × 2 (recent stress: yes/no) × 2 (BDNF Val^66^Met: Val/Val vs. Met carriers) ANOVA. CA and recent stress were entered as dichotomous (yes/no) variables in order to have a maximal number of subjects in each cell. Since gender, age, years of education, symptom severity of depression, presence of current MDD vs remitted MDD, presence of a current comorbid anxiety disorder, use of an antidepressant, exact time of morning blood withdrawal, and the duration of serum storage have been discussed as potential sources of between-subject variation in BDNF levels (Begliuomini et al. [@CR4]; Sen et al. [@CR38]; Trajkovska et al. [@CR42]), we statistically controlled for their possible confounding effects by adding these variables as covariates to the analysis. Significant interactions were followed up by independent *t* tests.

Secondly, because recent studies suggest that the symptomatology and causal pathways for MDD *without* comorbid anxiety disorder may be quite distinct to those for MDD *with* comorbid anxiety disorder(s) (see Gatt et al. [@CR16]), we repeated the same 2 (CA: yes/no) × 2 (recent stress: yes/no) × 2 (BDNF Val^66^Met: Val/Val vs. Met carriers) ANOVA in participants with (lifetime) MDD without comorbid anxiety (MDD−, *n* = 401) and individuals with (lifetime) MDD and comorbid anxiety disorders (MDD + ANX, *n* = 1,033), separately.

Finally, to asses dose--response relations between CA and recent stress and BDNF levels, additional ANOVAs were conducted in the case of significant main effects of CA and/or recent stress or interactions with BDNF Val^66^Met, based on three categories (no CA or recent life events vs one type of CA or recent life event vs two or more types of CA or recent life events).

Computations were performed in PASW version 18.0 (PASW, Chicago, IL, USA). Statistical significance was set at *P* \< .05 (two-sided). Effect sizes were presented as Cohen's *d* ([@CR10]).

Results {#Sec7}
=======

Demographics {#Sec8}
------------

Table [1](#Tab1){ref-type="table"} shows the demographical and clinical characteristics by Val^66^Met, reported history of CA, and recent stressful life events. Exposure to CA and recent stressful life events was independent of BDNF genotype (*P* = .13 and *P* = .74, respectively). Exposure to recent stressful life events tended to be reported somewhat more often in individuals with a history of CA (*P* = .07). Individuals who were homozygous for the Val allele had more years of education compared to individuals who carried a Met allele. Individuals who reported CA were of older age and more likely to be female, to have a current episode of MDD, to have more chronic MDD, to have greater symptom severity of MDD, and to have a comorbid anxiety and alcohol use disorder compared to individuals who did not report CA. Individuals reporting recent life events were of younger age, had less years of education, and were more likely to smoke, to have a current episode of MDD, to have chronic MDD, to have greater symptom severity, and to have a comorbid anxiety disorder (see Table [1](#Tab1){ref-type="table"}). No other main effects nor Val^66^Met × CA, Val^66^Met × recent stress, or Val^66^Met × CA × recent stress interactions were found.

Impact of childhood abuse, recent stress, and Val^66^Met on serum BDNF levels {#Sec9}
-----------------------------------------------------------------------------

Using a 2 (CA: yes/no) × 2 (recent stress: yes/no) × 2 (BDNF Val^66^Met: Val/Val vs. Met carriers) ANOVA on serum BDNF levels, we found no main effect of CA (*P* = .38) nor a main effect of Val^66^Met on BDNF levels (*P* = .33), but BDNF Val^66^Met moderated the effects of CA on serum BDNF levels (*F*~1,\ 1,416~ = 5.57, *P* = .018, see Fig. [1](#Fig1){ref-type="fig"}). Met carriers reporting CA had significantly lower levels of BDNF compared to Met carriers that did not report CA (*F*~1,\ 506~ = 4.19, *P* = .041, *d* = 0.19), whereas individuals reporting CA who were homozygous for the Val allele had similar levels of BDNF compared to homozygous Val carriers without CA (*P* = .12). Furthermore, in individuals reporting no CA, Met carriers had *higher* levels of BDNF compared to homozygous Val carriers (*F*~1,\ 629~ = 3.88, *P* = .049, *d* = 0.19), while in the CA group, Met carriers had similar levels of BDNF compared to homozygous Val carriers (*P* = .22). Exposure to recent stressful life events did not affect BDNF levels (*P* = .79). No other interaction effects were found (all *P*s \> .10). Fig. 1Mean values of serum levels of BDNF by exposure to Childhood Abuse (CA), recent stressful events, and BDNF Val^66^Met in the total group of life-time MDD-patients (*n* = 1,435)

### Dose--response associations between CA and BDNF {#Sec10}

To investigate a dose--response association between CA and BDNF levels in the Met carriers versus the Val/Val group, additional 3 (categories of CA: no CA (*n* = 613) vs. one type of CA (*n* = 310) vs. two or more types of CA (*n* = 512)) × 2 (BDNF Val^66^Met: homozygous Val/Val vs. Met carriers) ANOVA was conducted. An interaction was found between CA categories and Val^66^Met (*F*~2,\ 1,418~ = 2.99, *P* = .05). Post hoc comparisons showed that BDNF levels were only low in Met carriers when participants reported two or more types of CA compared to no CA (*P* = .032), but not when they reported one type of CA (*P* = .51), while in the homozygous Val carriers, no main effect of CA categories was found (*P* = .29, *data not shown*).

MDD without comorbid anxiety versus MDD with comorbid anxiety {#Sec11}
-------------------------------------------------------------

### MDD without comorbid anxiety {#Sec12}

We repeated the 2 (CA: yes/no) × 2 (recent stress: yes/no) × 2 (BDNF Val^66^Met: Val/Val vs. Met carriers) ANOVA on serum BDNF levels in individuals with an (lifetime) MDD *without* a comorbid anxiety disorder (MDD−, *n* = 402, see Fig. [2](#Fig2){ref-type="fig"}). In the MDD− group, recent stress did affect BDNF levels (*F*~1,\ 383~ = 7.19, *P* = .008, *d* = 0.29), indicating lower BDNF levels in individuals reporting one or more recent stressful life events (mean ± SD = 8.24 ± 3.20) compared to those who did not report negative life events (mean ± SD = 9.16 ± 3.06). Moreover, the interaction between CA and BDNF Val^66^Met was also present in the MDD− group (*F*~1,\ 383~ = 9.77, *P* = .002), with Met carriers who report CA having significantly lower serum levels of BDNF compared to Met carriers who did not report CA (*F*~1,\ 138~ = 10.03, *P* = .002, *d* = 0.44), whereas individuals reporting CA who were homozygous for the Val allele even had somewhat higher levels of BDNF compared to homozygous Val carriers without CA (*F*~1,\ 258~ = 3.82, *P* = .052, *d* = 0.23). Moreover, Met carriers with a reported history of CA showed *low* BDNF levels compared to homozygous Val carriers with reported CA (*F*~1,\ 173~ = 7.45, *P* = .007, *d* = 0.45), while Met carriers reporting no CA had *higher* BDNF levels compared to the nonabused homozygous Val carriers (*F*~1,\ 223~ = 5.34, *P* = .022, *d* = 0.23). There were no other main or interaction effects in the MDD− group. Fig. 2Mean values of serum levels of BDNF by exposure to Childhood Abuse (CA), recent stressful events, and BDNF Val^66^Met in the group of lifetime MDD-patients *without* comorbid anxiety disorders (*n* = 402)

### Dose--response associations between recent stress and BDNF in the MDD− group {#Sec13}

To evaluate whether there was a dose--response association between the number of reported recent life events and BDNF levels, an additional ANOVA was conducted on the three categories of recent stress: no (*n* = 232) vs one recent life event (*n* = 92) vs two or more life events (*n* = 78), which confirmed the effect of recent stress (*F*~2,\ 388~ = 3.17, *P* = .04). However, post hoc comparisons showed that BDNF was not affected in a dose-dependent way: whereas individuals reporting one life event had lower BDNF levels (mean ± SD, 8.19 ± 3.09) than those reporting no life event (mean ± SD, 9.11 ± 3.06; *P* = .018; *d* = 0.30), the group reporting two or more life events (mean ± SD, 8.53 ± 3.35) did not differ from the group reporting no or one life event (both *P*s \> .10).

### Dose--response associations between CA categories and BDNF in the MDD− group {#Sec14}

To investigate a dose--response association between CA and BDNF levels in Met carriers versus the homozygous Val group, an additional 3 (categories of CA: no CA (*n* = 225) vs one type of CA (*n* = 81) vs two or more types of CA (*n* = 96)) × 2 (BDNF Val^66^Met: homozygous Val/Val vs. Met carriers) ANOVA was conducted (see Fig. [3](#Fig3){ref-type="fig"}). An interaction was found between CA categories and Val^66^Met (*F*~3,\ 383~ = 6.47, *P* \< .0001), indicating that BDNF levels decrease in Met carriers with increasing types of CA (*F*~3,\ 132~ = 5.00, *P* = .003), while in the homozygous Val carriers, no main effect of CA categories was found (*P* = .11). Post hoc comparisons showed that BDNF levels were only low in Met carriers when participants reported two or more types of CA compared to no CA (*P* = .001, *d* =0 .63), but not when they reported one type of CA (*P* = .11). Moreover, Met carriers only had lower BDNF levels when reporting two or more types of CA compared to the Val/Val group that reported two or more types of CA (*P* = .006, *d* = 0.66), but not when reporting one type of CA (*P* = .46). Furthermore, a main effect of Val^66^Met also emerged (*F*~3,\ 383~ = 5.56, *P* = .019), with Met carriers having lower BDNF levels compared to Val/Val individuals, regardless of CA categories. Fig. 3Mean values of serum levels of BDNF by exposure to the number of Childhood Abuse (CA) types and BDNF Val^66^Met in lifetime MDD-patients *without* comorbid anxiety disorders (*n* = 402)

### MDD with comorbid anxiety {#Sec15}

The results of the same ANOVA in the MDD + ANX group showed a main effect of recent stress on BDNF levels (*F*~1,\ 1,014~ = 4.14, *P* = .042, *d* = 0.16). In contrast to the findings in the MDD− group, recent stress exposure was associated with *elevated* BDNF levels (mean ± SD, 9.26 ± 3.8) compared to not being exposed to recent stressful events (mean ± SD, 8.47 ± 3.4). Moreover, recent stress tended to interact with BDNF Val^66^Met (*F*~1,\ 1,014~ = 3.04, *P* = .082). No other main or interaction effects were significant in the MDD + ANX group.

### Dose--response associations between recent stress categories and BDNF in the MDD + ANX group {#Sec16}

To evaluate whether there was a dose--response association between the number of reported life events in the Val/Met vs. the Val/Val, an additional 3 (categories of recent stress: no (*n* = 606) vs one recent life event (*n* = 246) vs two or more life events (*n* = 181)) × 2 (BDNF Val^66^Met: Val/Val vs. Met carriers) ANOVA was conducted. Here, only a trend for life events categories was found (*F*~2,\ 1,016~ = 2.33, *P* = .098) and no interaction with BDNF Val^66^Met (*P* = .29). When comparing the means for the three recent stress groups post hoc, only individuals reporting one life event (mean ± SD, 9.58 ± 4.00) had higher BDNF levels than those reporting no life events (mean ± SD, 8.98 ± 3.42; *P* = .031), whereas the group reporting two or more life events (mean ± SD, 9.14 ± 3.42) did not differ from the group reporting 1 or no life event (both *P*s \> .10).

Discussion {#Sec17}
==========

The main new result of this study is that the impact of CA on serum BDNF levels appears to be dependent on variations on the BDNF Val^66^Met polymorphism, at least in individuals with (lifetime) MDD without comorbid anxiety. In BDNF Met carriers, exposure to CA was associated with reduced serum levels of BDNF, and these differences were most pronounced in Met carriers who also reported negative life event(s) in the past year (see Fig. [2](#Fig2){ref-type="fig"}). In addition, these BDNF reductions associated with CA were linear in nature, so that BDNF levels were lowest in Met carriers reporting two or more types of CA. Moreover, these associations were not accounted for by the presence of a current diagnosis of MDD or by other potentially confounding factors, such as gender, or the use of an antidepressant, as these factors were added as covariates in the analyses and did not differ between the homozygous Val/Val and the Met carriers. The Val/Val group, on the other hand, did not show reductions in BDNF levels related to CA, and in the MDD group without comorbid anxiety, BDNF levels were even higher in Val/Val participants reporting CA. Taken together, these findings are in line with the idea that Met carriers are more sensitive to stress-induced downregulation of BDNF.

A second main finding is that exposure to stressful events that occurred in the past year reduced BDNF levels, independent of variations on the BDNF Val^66^Met polymorphism, at least in the MDD group without comorbid anxiety. These results extend the finding of two previous studies showing lowered BDNF levels in bipolar patients reporting negative life events (Kauer-Sant'Anna et al. [@CR23]), and in women with high risk of depression reporting recent life events (Trajkovksa et al. [@CR43]). In the group with comorbid anxiety, recent stress exposure was associated with increased BDNF levels, however. Moreover, while CA was associated with reduced BDNF in the Met carriers, BDNF levels were not affected by CA in the comorbid group. These findings seem to suggest that comorbid anxiety disorder may counteract the downregulation of BDNF associated with CA and recent stressful event. So far, it is unclear how this relates to the symptomatology of MDD with and without comorbid anxiety, particularly because CA has specifically been linked to comorbidity of MDD and anxiety disorders (Hovens et al. [@CR20]). Moreover, some studies have associated the Val/Val polymorphism with patterns of anxiety, rather than with depressive symptoms (Gatt et al. [@CR16]), but in the group with comorbid anxiety disorders, we did not find any indications that Val/Val individuals have lower BDNF levels.

Although it should be taken into account that this is a cross-sectional study, preventing causal inferences about the impact of CA, it is remarkable that exposure to CA, which occurred in many individuals more than 25 years ago, is associated with decreased BDNF levels, at least in Met carriers without comorbid anxiety disorders. These reductions of serum BDNF levels in individuals with reported CA suggest that exposure to chronic stress during childhood may lead to a long-lasting downregulation of the neurotrophic system, which might be further reduced by recent stressful events. These results extend the findings of previous studies showing lower levels of peripheral BDNF in patients with current MDD and a history of CA (Grassi-Oliveira et al. [@CR17]). Since variations at the Val^66^Met locus were not taken into account in this study, it remains unclear whether the effects of CA were mainly driven by Met carriers, as might be expected on the basis of our results.

The finding of reduced BDNF levels in Met carriers is also of interest when considered in the context of previous findings, indicating that Met carriers are particularly vulnerable to the impact of CA with respect to depressive symptoms (Gatt et al. [@CR16]; Kaufman et al. [@CR24]; Wichers et al. [@CR46]) and enhanced loss of hippocampal-lateral prefrontal gray matter (Gatt et al. [@CR16]), given that low BDNF levels are associated with MDD (Sen et al. [@CR38]). Moreover, reductions in BDNF expression can have a direct impact on neuronal growth and plasticity in frontohippocampal networks (Murakami et al. [@CR30]; Roceri et al. [@CR36]; Song et al. [@CR40]; Smith et al. [@CR39]). It should be noted that, in our sample, no associations were found between Met carriers and higher depression severity after CA, however, which is consistent with some recent studies (see Aguilera et al. [@CR1]; Nederhof et al. [@CR31]). Definitely, longitudinal studies are needed to further unravel the developmental trajectories relating exposure to CA and recent life events to low BDNF levels and altered brain structures and functioning.

One other interesting observation is that variations on the BDNF Val^66^Met polymorphism itself were not directly associated with variations in BDNF levels even though, among individuals reporting no CA, Met carriers had *higher* BDNF levels compared to homozygous Val carriers. Very few studies in humans investigated the association between the BDNF Val^66^Met polymorphism and serum BDNF levels. One study in psychological healthy individuals also reported enhanced serum BDNF levels in Met carriers compared to Val/Val individuals (Lang et al. [@CR27]). Two other studies did not find an association between the Val^66^Met polymorphism and variations in peripheral BDNF levels, not in a sample of depressed patients (Duncan et al. [@CR14]) nor among healthy twins with and without a co-twin history of affective disorder (Vinberg et al. [@CR44]), even though in this last study, BDNF levels were higher among a subgroup of Met carriers at high risk for depression or bipolar disorder. Taken together, findings regarding associations between the Val^66^Met polymorphism and variations in peripheral BDNF levels in humans are mixed. This could be due to the fact that, in previous studies, neither CA nor exposure to recent stressful events has been taken into account. Furthermore, this might also be related to the fact that the direct associations between Val^66^Met and BDNF levels, if anything, appear to be rather small in individuals reporting no CA (in our study *d* = 0.19) and thus can only be detected in large samples.

In sum, this study has shown that CA is associated with reduced BDNF levels in Met carriers with lifetime MDD (without comorbid anxiety), whereas serum BDNF levels of Val/Val carriers do not seem to be affected by CA. A number of limitations should be taken into account when evaluating these findings. First, the reliability of participants' recall of events from childhood may vary, given the long time gap between occurrence and recall. Self-reported CA requires caution when interpreting the results, although Goodman et al. ([@CR18]) observed good reliability among psychiatrically ill women. Related to this, one cannot rule out that the association between CA or recent stress and low BDNF levels in individuals with lifetime MDD could (in part) be spurious, in the sense that individuals with a current depressed mood might have low BDNF levels and also experience life events in a (more) negative way, without these factors being directly related to each other. We do not consider this possibility very likely, however. First of all, we have previously shown that, in the NESDA sample, the association between negative life events and depression is independent of current mood state (Spinhoven et al. [@CR41]). Moreover, in all statistical analyses, we added current vs remitted MDD as a covariate, and the associations between life events and BDNF remain statistically significant when taking current mood state into account. A longitudinal design would be optimal to assess whether predifferences--postdifferences in serum BDNF are directly affected by stressful events. Another limitation is that we assessed serum BDNF levels, which may not be a direct measure of central BDNF, even though previous studies in animals showed that BDNF can cross the blood--brain barrier in both directions (Pan et al. [@CR32]) and a strong association has been reported between central and peripheral BDNF levels (Karege et al. [@CR21]). A third limitation is that we only assessed the Val^66^Met variant, whereas there are more loci on the BDNF gene that might be associated with variations in serum BDNF levels. Moreover, gene × gene interactions, particularly with the 5HTT-LPR polymorphism, were not addressed in this study, whereas these interactions have been shown to be relevant in predicting depression severity in combination with CA in some studies (see Kaufman et al. [@CR24]; Wichers et al. [@CR46]), although not in others (Gatt et al. [@CR16]).

Despite the considerations mentioned above, the findings of this study highlight the importance of investigations that focus on integrating candidate genes, BDNF levels, and environmental stressors and provide new and important evidence to suggest that a chain of events, commencing with G × E interactions and their impact on (set points of) BDNF, may lead to low BDNF levels in patients with lifetime MDD.
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